Development of improved models for phosphodiesterase-4 inhibitors with a multi-conformational structure-based QSAR...

Area of Science:

• Medicinal Chemistry
• Computational Chemistry
• Drug Discovery

Background:

• Phosphodiesterase-4 (PDE-4) is a key drug target for chronic obstructive pulmonary disorder (COPD) and neurodegenerative diseases.
• Existing quantitative structure-activity relationship (QSAR) models have limitations in accurately predicting the efficacy of PDE-4 inhibitors.
• Molecular flexibility is a critical factor in inhibitor binding that traditional QSAR methods often fail to adequately address.

Purpose of the Study:

• To develop improved QSAR models for phosphodiesterase-4 (PDE-4) inhibitors.
• To incorporate molecular flexibility into structure-based QSAR modeling using a multi-conformational approach.
• To enhance the predictive power of QSAR models for identifying novel PDE-4 drug candidates.

Main Methods:

• Development of a novel multi-conformational structure-based pharmacophore key (MC-SBPPK) method.
• Calculation of PDE4-specific molecular descriptors based on pharmacophore feature matching with the target binding pocket.
• Application of an iterative partial least square (iPLS) procedure to solve the nonlinear regression problem arising from multiple conformations.

Main Results:

• Developed robust and predictive QSAR models for 35 PDE-4 inhibitors.
• Demonstrated superior performance compared to traditional ligand-based QSAR techniques and previous SBPPK methods.
• The MC-SBPPK method effectively addresses molecular flexibility in QSAR modeling.

Conclusions:

• The developed MC-SBPPK QSAR models provide enhanced predictive accuracy for PDE-4 inhibitors.
• These models represent a valuable addition to the existing QSAR toolkit for PDE-4 drug discovery.
• The improved models will aid in the identification and design of new therapeutic agents targeting PDE-4.